Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSAGE chemoradiation in elderly oesophageal cancer
2024-514998-21-00Phase 2Authorised
- Sponsor
- CHRU Nancy
- Start
- Jul 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and paclitaxel in esophageal cancer, sponsored by CHRU Nancy. Primary endpoint: Dose-limiting toxicity and recommended Phase II dose. Planned start Jul 2024; status: authorised.
02
Drugs
carboplatinpaclitaxel
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on 2024-514998-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514998-21-00.